© Springer Nature Switzerland AG 2021
C. S. Foster et al. (eds.)Uveitishttps://doi.org/10.1007/978-3-030-52974-1_10

10. Relapsing Polychondritis

May Ibrahim El Rashedy1  
(1)
Department of Ophthalmology, Cairo University Hospitals, Cairo, Egypt
 
 
May Ibrahim El Rashedy
Keywords
Relapsing polychondritisUveitis

Overview

  • Definition: Recurrent episodic autoimmune inflammation against collagen types II, IX, and XI, involving cartilages and proteoglycan-rich structures, such as the eye, heart, blood vessels, and inner ear
    • Ocular disease (50–67%): 30% can be the initial presentation of the disease. Most commonly involves the episclera and sclera, but may affect any ocular structure

    • Auricular chondritis (83–95%): unilateral or bilateral auricular pain and swelling; associated with hearing loss, tinnitus, and vertigo from inner ear involvement

    • Nonerosive arthritis (52–85%): asymmetric and often migratory polyarthritis lasting weeks to months

    • Nasal chondritis (33–72%): sudden painful onset with mild epistaxis

    • Laryngotracheal disease (30–67%): varies from asymptomatic to life-threatening complications; hoarseness, aphonia, wheezing, inspiratory stridor, nonproductive coughing, dyspnea

    • Skin/mucosal disease (0–83%): nonspecific and range from aphthous ulcers, nodules on the limbs, to purpura and pustules

    • Cardiovascular disease (6–23%): chest pain, silent MI, arrhythmias, heart block, and syncope from aortitis

    • Neurological disease (0–10%): due to vasculitis of the peripheral nervous system or CNS; peripheral neuropathy, cranial nerve palsy, hemiplegia, and seizures

  • Symptoms
    • Pain

    • Redness

    • Photophobia

    • Blurry vision

  • Laterality
    • Unilateral or bilateral

  • Course
    • Relapsing and remitting

  • Age of onset
    • 40–50s but can occur in childhood

  • Gender/race
    • Slight female preponderance

    • Equal frequency across races

  • Systemic association
    • HLA-DR4 and HLA-DR6

    • A third of cases coexist with other autoimmune diseases, including systemic vasculitis of small, medium, and large vessels; rheumatoid arthritis; ankylosing spondylitis; systemic lupus erythematosus; antiphospholipid syndrome; inflammatory bowel diseases; Behçet’s disease (“MAGIC” syndrome: mouth and genital ulcers with inflamed cartilage)

    • RP can also be seen with myelodysplastic syndrome, typically in older males (Table 10.1)

Table 10.1

McAdam/Michet diagnostic criteria of RP with Damiani-Levine modifications

Recurrent bilateral auricular chondritis

Nonerosive seronegative inflammatory polyarthritis

Nasal chondritis

Ocular inflammation

Respiratory tract chondritis

Cochlear and/or vestibular dysfunction

One of the following is required to establish diagnosis:

 ≥3 of the above criteria

 ≥1 of the above criteria with positive histologic confirmation

 Chondritis in ≥2 separate anatomic locations with response to steroids and/or dapsone

Exam: Ocular

Anterior Segment

  • Episcleritis (39%)

  • Scleritis (14%)
    • First disease manifestation in 2–3% of RP patients

    • Stronger marker of systemic inflammation

    • Diffuse, nodular, or necrotizing

    • Scleromalacia after repeat scleritis

  • Peripheral ulcerative keratitis (PUK)
    • Like scleritis, presence of PUK calls for more aggressive treatment

  • Non-granulomatous anterior uveitis

  • Conjunctivitis (10%)

Posterior Segment

  • Unusual, but retinal vasculitis, vascular occlusion, exudative RD, and inflammatory or ischemic optic neuropathy have been reported

Exam: Systemic

  • Auricles: diffusely violaceous and erythematous with sparing of non-cartilaginous ear lobes, +/− sensorineural hearing loss

  • Joints: nondeforming and nonerosive arthritis which affect mostly the metacarpophalangeal, proximal interphalangeal joints and knees Sternoclavicular, costochondral, and manubriosternal articulations are also typically involved

  • Nose: saddle-nose deformity (17–29%) and a flat nasal tip, more common in men and younger patients

  • Large airways: (sub)glottic, laryngeal, or tracheobronchial inflammation with luminal encroachment. Laryngeal collapse during inspiration and/or tracheal collapse during expiration

  • Skin: urticaria, angioedema, erythema multiforme, livedo reticularis, panniculitis, and erythema nodosum

Imaging

  • FA: retinal vascular occlusion or peripheral vasculitis

  • B-scan: sclerochoroidal thickening in areas of posterior scleritis

Laboratory and Radiographic Testing

There is no specific lab test for RP; diagnosis is based on the combination of clinical and radiographic findings, occasionally assisted with cartilage biopsy.
  • Labs
    • Elevated CRP is most common, but 1 in 10 patients may have normal acute phase reactants during acute disease flare

    • Serum antibodies to type II collagen: present in 20–50%, but not specific nor sensitive, and only performed in a few laboratories

    • ANA: present in 20–60%; homogenous or speckled pattern

    • ANCA: may be present in RP, but granulomatosis with polyangiitis should be strongly considered if ANCA+, especially if it is c-ANCA and associated with anti-PR3 antibodies

  • Imaging
    • Chest radiography: laryngotracheal bronchial wall thickening, airway stenosis, and cartilaginous calcification

Differential Diagnosis

  • Granulomatosis with polyangiitis

  • Polyarteritis nodosa

  • Rheumatoid arthritis

Treatment

  • Mild disease with diffuse anterior scleritis and involvement of nasal/auricular cartilages
    • NSAIDs

    • Dapsone

  • Severe disease with nodular/necrotizing scleritis and involvement of respiratory tract cartilages, inner ear, and vital organs
    • Corticosteroids

    • Methotrexate

    • Azathioprine

    • Mycophenolate mofetil

    • Leflunomide

    • Cyclosporine A

    • Cyclophosphamide (life-threatening disease with necrotizing scleritis, laryngotracheal involvement, and aortitis)

    • Biologics
      • TNF-alpha inhibitors, mainly infliximab, appear effective in many cases after conventional immunosuppressants failed or were poorly tolerated

      • Anakinra (anti-IL-1R), tocilizumab (anti-IL-6R), and abatacept (co-stimulatory signaling pathway inhibitor) are effective in fewer reports

      • Rituximab (anti-CD20) appears ineffective

    • Plasmapheresis and IVIg used in some cases

Referral/Co-management

  • Rheumatology

  • ENT

  • Pulmonary